文献速递前列腺癌

五点评分系统对前列腺MRI诊断准确性的评估:基于MRI/超声图像融合靶向活检结果

Diagnostic accuracy of a five-point Likert scoring system for magnetic resonance imaging (MRI) evaluated according to results of MRI/ultrasonography image-fusion targeted biopsy of the prostate.
PubMed 文献 · BJU Int · 2017-08-16

该研究回顾性分析了629例患者共1218个MRI检出病灶,以MRI/超声图像融合靶向活检为参考标准,评估五点评分系统对临床显著前列腺癌(CSPC)的检测准确性。结果显示,Likert评分1-5分的总体癌症检出率分别为12%、13%、22%、50%和59%,CSPC检出率分别为4%、4%、12%、33%和48%。评分与癌症检出率及CSPC检出率呈强正相关,且在不同经验水平的放射科医生间,Likert 4-5分病灶的检出率存在显著差异。

要点

  • Likert评分1-5分与总体癌症检出率及CSPC检出率均呈强正相关。
  • Likert 4-5分病灶中,经验更丰富的放射科医生总体癌症检出率63% vs 经验较少者35%(P=0.001),CSPC检出率47% vs 29%(P=0.027)。
  • Likert评分1-2分病灶占48%(n=581),3分占35%(n=428),4-5分占17%(n=209)。

核心结论

  • 总体癌症和CSPC的检出率与Likert五点评分强相关。
  • 不同经验水平的放射科医生之间,这些癌症检出率存在显著差异。

研究设计与样本

  • 回顾性研究,纳入2012年10月至2015年8月间接受MRI/超声图像融合靶向活检的629例患者,共1218个MRI检出病灶。
  • 采用3-Tesla MRI,由8名经验水平不一的放射科医生之一独立报告,并按五点评分Likert量表评分。
  • 所有Likert评分1-5分的病灶均前瞻性定义为MRI/超声图像融合靶向活检的靶点。

主要发现

  • 患者中位年龄64岁,PSA水平6.97 ng/mL,估计前列腺体积52.2 mL。
  • 1218个病灶中,48%(n=581)评为Likert 1-2分,35%(n=428)为Likert 3分,17%(n=209)为Likert 4-5分。
  • Likert评分1-5分的总体癌症检出率分别为12%、13%、22%、50%和59%,CSPC检出率分别为4%、4%、12%、33%和48%。
  • 五点评分与总体癌症检出率(r=0.949,P=0.05)和CSPC检出率(r=0.944,P=0.05)呈强正相关。
  • 在Likert 4-5分病灶中,经验更丰富的放射科医生与经验较少者相比,总体癌症检出率63% vs 35%(P=0.001),CSPC检出率47% vs 29%(P=0.027)。

关键数值与推荐

  • CSPC定义为Gleason评分≥7。
  • Likert评分1-5分对应的总体癌症检出率依次为12%、13%、22%、50%、59%。
  • Likert评分1-5分对应的CSPC检出率依次为4%、4%、12%、33%、48%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the accuracy of a magnetic resonance imaging (MRI)-based Likert scoring system in the detection of clinically significant prostate cancer (CSPC), using MRI/ultrasonography (US) image-fusion targeted biopsy (FTB) as a reference standard. PATIENTS AND METHODS: We retrospectively reviewed 1218 MRI-detected lesions in 629 patients who underwent subsequent MRI/US FTB between October 2012 and August 2015. 3-Tesla MRI was independently reported by one of eight radiologists with varying levels of experience and scored on a five-point Likert scale. All lesions with Likert scores 1-5 were prospectively defined as targets for MRI/US FTB. CSPC was defined as Gleason score ≥7. RESULTS: The median patient age was 64 years, PSA level 6.97 ng/mL and estimated prostate volume 52.2 mL. Of 1218 lesions, 48% (n = 581) were rated as Likert 1-2, 35% (n = 428) were Likert 3 and 17% (n = 209) were Likert 4-5. For Likert scores 1-5, the overall cancer detection rates were 12%, 13%, 22%, 50% and 59%, respectively, and the CSPC detection rates were 4%, 4%, 12%, 33% and 48%, respectively. Grading using the five-point scale showed strong positive correlation with overall cancer detection rate (r = 0.949, P = 0.05) and CSPC detection rate (r = 0.944, P = 0.05). By comparison, in Likert 4-5 lesions, significant differences were noted in overall cancer detection rate (63% vs 35%; P = 0.001) and CSPC detection rate (47% vs 29%; P = 0.027) for the more experienced vs the less experienced radiologists. CONCLUSIONS: The detection rates of overall cancer and CSPC strongly correlated with the five-point grading of the Likert scale. Among radiologists with different levels of experience, there were significant differences in these cancer detection rates.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Shin T, Smyth TB, Ukimura O, et al. Diagnostic accuracy of a five-point Likert scoring system for magnetic resonance imaging (MRI) evaluated according to results of MRI/ultrasonography image-fusion targeted biopsy of the prostate. BJU Int. 2017. PMID: 28749070. doi:10.1111/bju.13972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。